Date Title Description PDF
24 Jul 2025 On P&L The Company releases the press release related to the first half of 2025 financial results Download
24 Jul 2025 On P&L The Company releases the first half 2025 financial results presentation Download
25 Mar 2025 On business and financial situation The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day Download
25 Feb 2025 On P&L The Company releases the press release related to the full year 2024 financial results Download
25 Feb 2025 On P&L The Company releases the full year 2024 financial results presentation Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
21 Feb 2012 Información sobre resultados (2) Download
21 Feb 2012 Información sobre resultados Download
21 Feb 2012 Informe Anual de Gobierno Corporativo Download
15 Feb 2012 Cambios en política de inversión, áreas de negocio y líneas de productos Download
22 Dec 2011 Composición del Consejo de Administración Download

Pages